Search Technologies

The National Cancer Institute’s Chemical Biology Laboratory seeks partners interested in collaborative research to co-develop nitric oxide (NO) based prodrugs for the treatment of lung cancer.

Researchers at the National Cancer Institute found that the absence of CD47 enhances stem cell renewal in vitro and in vivo by increasing expression of four stem cell transcription factors.

The Laboratory of Cancer Biology and Genetics of the National Cancer Institute (NCI) seeks parties interested in licensing methods for selecting cancer patients for combination therapy.

The National Cancer Institute's Urologic Oncology Branch seeks interested parties to co-develop antagonists to VEGF-A and hepatocyte growth factor (HGF) that block signal transduction and associated cellular responses.

The NCI seeks partners interested in in-licensing or co-development collaboration on CD47-targeting therapeutics for cardioprotection and autophagy modulation.

Pulmonary surfactant plays a critical role in preventing alveolar collapse by decreasing surface tension at the alveolar air-liquid interface. Surfactant deficiency contributes to the pathogenesis of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), common disorders that can afflict patients of all ages and carry a mortality rate greater than 25%. Excess surfactant leads to pulmonary alveolar proteinosis. NCI investigators created a G-protein coupled receptor GPR116 mutant mouse model and showed that GPR116 plays a previously unexpected, essential role in maintaining normal surfactant levels in the lung. The National Cancer Institute seeks partners interested in collaborative research to license surfactant modulating agents for the treatment of surfactant related lung disorders.

The National Cancer Institute seek parties interested in in-licensing and/or collaborative research to develop and commercialize cell labeling, cell tracking, cell trafficking, cell-based therapy, and PET imaging for cancer.

methods of diagnosing and treating malignant adrenocortical tumors, including adrenocortical carcinoma, using miRNA

Despite the growing number of biomarkers that are used for diagnosing and treating carcinomas in general, cancers of the thymus are still diagnosed, stratified and treated by a costly combination of histology, surgery and radiological procedures.  The lack of qualified biomarkers associated with thymomas and thymic carcinomas has also hampered the development of targeted therapies. The National Cancer Institute seeks partners interested in licensing or collaborative research to co-develop a prognostic PCR based test for thymic malignancies.